Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > ARCHIVE
ARCHIVE
- IMSJ, ACNielsen to Cooperate in OTC Drug Market Surveys
December 15, 2003
- WORLD NEWS IN BRIEF
December 15, 2003
- Nikken Chemicals: 30%-decrease in Sales of Theodur Hurts Sales, Profits
December 8, 2003
- Sundrug: Sales, Ordinary Profits Up 16.5%, 3.8% Respecticely
December 8, 2003
- ON THE MOVE
December 8, 2003
- Kobayashi: Operating Profits Down 4.4%, Hurt by Cool Summer
December 8, 2003
- BIO-Asia Clinical Stage Partnering Conference to Give Makers Good Chance: Mr Tanaka, Consultant
December 8, 2003
- OTC NEWS IN BRIEF
December 8, 2003
- Kaken to Remain Independent, Focus on Niche Markets: President Inui
December 8, 2003
- MEDICAL DEVICE NEWS IN BRIEF
December 8, 2003
- EU's Clinical Trial Directive Discussed: Quintiles Seminar
December 8, 2003
- DIAGNOSTIC NEWS IN BRIEF
December 8, 2003
- Resistance to Use of Contract MRs Weakening: Fuji-keizai Survey
December 8, 2003
- WORLD NEWS IN BRIEF
December 8, 2003
- BUSINESS NEWS IN BRIEF
December 8, 2003
- We Wish to Become a Global Mega-Player after 2005: Dr Aoki of Fujisawa
December 8, 2003
- Approval of 3 Drugs Including Atazanivir Recommended
December 8, 2003
- Semi-annual Business Result
December 8, 2003
- ICH-6 in Osaka Focuses on New Horizons and Future Challenges (2)
December 8, 2003
- Non-consolidated Sales of 29 Top Companies Down 0.3%
December 8, 2003
ページ
Japan’s pharmaceutical industry is undergoing a structural shift in its workforce, with the role of sales reps shrinking while production…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…